Healthy Fertility (Women's)
Healthy Fertility (Women's), NPN 80090943: natural health product licensed in Canada. Medicinal ingredients: Riboflavine, Camellia sinensis, Vitamine E, Ubiquinol.
If this product were sold in France
- Declared dose above a limit
Vitamine B6: up to 6 mg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 2 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Declared dose above a limit
Fer: up to 18 mg a day according to the dosing instructions published by Health Canada (3 unités posologiques par jour au plus, pour les adultes), above the maximum dose of 14 mg set in France for a food supplement (2006 Order, not revised since November 2006).
arrêté du 9 mai 2006, annexe III. French orders of 9 May 2006 and 14 November 2006 as published in the Official Journal (maximum daily doses), retrieved 21 October 2026.
- Legal conditions
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026, source updated 26 November 2025.
- Legal conditions
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Riboflavine Source : Riboflavine | 1 milligramme | 3,000 µg |
| Camellia sinensis Source : Feuille Extract : Matériel brut sec Extraction ratio : 30:1 Dry plant equivalent : 3,000 milligramme Potency : 2 % Caffeine | 100 milligramme | Not calculated |
| Vitamine E Source : d-alpha tocophérol | 100 Unités internationales | Not calculated |
| Vitamine E Source : d-alpha tocophérol | 67.11 mg AT | Not calculated |
| Ubiquinol Source : Ubiquinol | 100 milligramme | Not calculated |
| Vitamine B6 Source : Pyridoxal 5'-phosphate | 2 milligramme | 6,000 µg |
| Zinc Source : Citrate de zinc | 3.5 milligramme | 10,500 µg |
| Folate Source : Acide folique | 0.133 milligramme | Not calculated |
| Fer Source : Citrate de fer (II) | 6 milligramme | 18,000 µg |
| L-arginine Source : Anas falcata - plume | 233 milligramme | Not calculated |
| Camellia sinensis Source : Feuille Potency : 50 % (-)-Epicatechin | Not specified | Not calculated |
Non-medicinal ingredients
Hypromellose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 1 Capsule | 3 days |
Uses authorised in Canada
Source of antioxidant(s) / Provides antioxidant(s) that help(s) fight/protect 9cell) against/reduce (the oxidative effect of/the oxidative damage caused by cell damage caused by ) free radicals. Helps to reduce the risk of neural tube defects when taken daily at least three months prior to becoming pregnant and during early pregnancy. Helps to support normal early development of the fetal brain and spinal cord. Used in Herbal Medicine to help relieve premenstrual symptoms. Used in Herbal Medicine as a hormone normaliser to help stabilise menstrual cycle irregularities. Used in Herbal Medicine to help relieve symptoms associated with menopause, such as hot flushes.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Cautions and Warnings
If you are taking blood pressure medication, consult a health care practitioner prior to use. If you are taking blood thinner medication, consult a health care practitioner prior to use. If you have a liver disease, a kidney disease, or a seizure disorder, consult a healthcare practitioner prior to use. Stop use if you develop symptoms of liver trouble such as yellowing of the skin/eyes (jaundice), stomach pain, dark urine, sweating, nausea, unusual tiredness and/or loss of appetite and consult a health care practitioner. If you have an iron deficiency, consult a health care practitioner prior to use. If you have a history of non-melanoma skin cancer, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you are taking hormone-containing medications such as progesterone preparations, oral contraceptives or hormone replacement therapy. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you are pregnant or breastfeeding. Keep out of reach of children. There is enough iron in this package to seriously harm a child. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if you suffer from cardiovascular diseases , and are attempting an increase in physical activity or if your cardiovascular condition worsens. Consult a health care practitioner/health care provider/health care professional/doctor/physician prior to use if are taking medication for cardiovascular disease erectile dysfunction and or blood thinners. To exclude the diagnosis of a serious cause of infertility consult your health care practitioner prior to use.
- Contra-Indications
Do not use if you have had a heart attack/myocardial infarction. Stop use if hypersensitivity occurs.
Product record
- Licence holder
- Luvolux Inc.
- NPN or DIN-HM
- 80090943
- Status
- Inactive licence
- Licence date
- 25 February 2019
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
Source
Official Health Canada record, licence 80090943
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ubiquinol
Read the warning, when it applies and the studies cited
UBIQUINOL
Route of administration: Oral
Cautions and warnings
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood pressure medication (Langsjoen and Langsjoen 2008; Rosenfeldt et al. 2007; Engelsen et al. 2003; Singh et al. 1999; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (6)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, Watts GF. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. Journal of Human Hypertension 2007;21(4):297-306. PubMed Meta-analysis
- Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS. Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. Journal of Human Hypertension 1999;13(3):203-208. PubMed Randomised trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Applies to products providing more than 100 mg of Ubiquinol, per day.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Langsjoen and Langsjoen 2008; Engelsen et al. 2003; Landbo and Almdal 1998; Spigset 1994).
Sources cited by Health Canada (4)
- Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment. A randomized, double-blind, placebo-controlled cross-over trial. Ugeskr Laeger 2003;165(18):1868-1871 (in Danish). PubMed Randomised trial
- Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger 1998;160(22):3226-3227 (in Danish). PubMed Case report
- Langsjoen PH, Langsjoen AM. Supplemental ubiquinol in patients with advanced congestive heart failure. Biofactors 2008;32(1-4):119-128. PubMed Clinical trial
- Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet 1994;344(8933):1372-1373. PubMed Case report
Condition of application: Migraine prophylaxis/prevention.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if migraine frequency increases and associated nausea and vomiting persist or worsen.
They concern the ingredient, not this product or its dose. They do not replace medical advice.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Healthy Fertility (Women's) (Luvolux Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80090943-healthy-fertility-women-s, updated 25 February 2019.